opinions within the academic community led the ACCP to revise the nomenclature, resulting in the adoption of the term UACS. There remains ongoing discourse regarding the appropriate terminology to delineate the experience of postnasal drip in relation to coughing [5, 8]. The reason why the European Respiratory Society (ERS) does not dene UACS is that postnasal drip cannot fully explain the cough and some patients with postnasal drip do not cough. UACS and postnasal drip syn­drome are classied as “rhinitis/rhinosinusitis” or upper respiratory tract diseases causing cough according to ERS [3, 5].

these medications include anticholinergic properties, particularly in the case of rst­generation antihistamines. The utilization of ipratropium bromide nasal spray may be considered in situations when contraindications are present or when alternative treatment options are deemed necessary. First generation antihistamines and decon­gestants may also provide relief for post viral cough resulting from a viral upper respiratory tract illness. Additionally, studies have demonstrated the potential ben­ets of Montelukast in the treatment of post viral cough. The management of symp­toms associated with chronic rhinosinusitis often involves the use of nasal saline, topical nasal corticosteroids, and antibiotics. In certain instances where conven­tional medical interventions are ineffective, the necessity for endoscopic sinus sur­gery may arise [10]. Insufcient data exist to establish a denitive dosage or duration for the administration of non-sedating or sedative H1-histamine receptor antagonist treatment. Two distinct studies have examined the improvement in cough score at different time intervals, indicating that there is currently no universally accepted standard period for medical therapy. In a study involving a cohort of 20 patients presenting with AR, characterized by cough and rhinoconjunctivitis, the patients underwent a 4-week treatment regimen involving the administration of loratadine, with the evaluation of cough frequency and severity as the primary outcome mea­sures. At the conclusion of the trial period, a notable enhancement in both measures was seen in comparison to the placebo group [11]. A cohort of individuals present­ing with a persistent cough and concurrent eosinophilic bronchitis, commonly referred to as atopic cough, was studied. A noteworthy reduction in cough symp­toms was observed after 1week of treatment with non-sedating antihistamines [12]. It is postulated that the development of UACS may be attributed to many variables, including postnasal drip, persistent inammation of the airway, and heightened sen­sitivity of the sensory nerves. Further research is required to distinguish the effects of distinct factors within, including thermal, mechanical, or chemical stimuli, on the development of chronic cough [5, 13]. The use of targeted therapy directed at par­ticular receptors, such as transient receptor potential vanilloid 1 (TRPV1), has the potential to enhance symptom relief in individuals who exhibit resistance to conven­tional antihistamine and decongestant treatments [13].

The utilization of saline irrigations has been shown to enhance the elimination of pathogens in the nasal passage and reduce the presence of inammatory mediators. The use of saline irrigation is supported by recommendations for the treatment of CRS due to its relative efcacy and low risk. Saline irrigation can be used as a stand­alone treatment or as an additional therapy in the management of children (espe­cially under 6years old) with CRS [14, 15].